Compare Johnson & Johnson (JNJ) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Clear Secure Inc — how do they compare? Johnson & Johnson trades at $261.44 (market cap $618.09B), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Johnson & Johnson is far larger — about 139.2× Clear Secure Inc's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Clear Secure Inc for 19 Days on average.
| JNJ | YOU | |
|---|---|---|
Market Cap | $618.09B | $4.44B |
Volume | 6,050,983 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $278.43 | $62.36 |
52-Week Low | $186.00 | $29.61 |
Typical Hold Time | 129 Days | 19 Days |
Enterprise Value | $646.37B | $3.59B |
Dividend Yield | 2.09% | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $256.48, down 0.76% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 28.45% net profit margin and consistent revenue growth to $94.19B in 2025. Analyst consensus remains positive with a $286.53 price target, though technical indicators show resistance at $258 and support at $253. Recent news highlights pipeline strength including Icotyde's $4.5B peak sales potential (Bank of America, 2026-09-29).
JNJ presents a compelling long-term investment with diversified healthcare exposure and dividend stability, though near-term technical weakness and patent cliff concerns warrant caution. The 52.5% buy rating from analysts reflects confidence in innovation pipeline, while debt-to-asset ratio increase to 24.06% merits monitoring. Upside potential exists if Q3 earnings beat expectations on October 13.
Clear Secure (YOU) trades at $43.08, up 1.17% with strong fundamentals including 27% revenue growth and expanding profitability. The stock shows mixed technical signals with bullish overall momentum but overbought RSI levels. Recent Q2 earnings beat expectations with $0.49 EPS versus $0.40 estimate, while analyst consensus targets $61.40 representing 43% upside potential.
Outlook remains positive with accelerating membership growth and new corporate partnerships driving expansion. Key risks include competitive pressure in identity verification and potential execution challenges. The stock offers growth exposure but requires monitoring of technical overbought conditions and quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
